SYLOGENT ACQUIRES CROSS DEVICE VIDEO PLAYER
NOVEMBER 30, 2011 - MARKETWIRE
NEWTOWN, PA--(Marketwire - Nov 30, 2011) - Sylogent today announced that it acquired the assets of SonicPlayer, LLC, specifically its cross-device media player that broadcasts video across any mobile device or computer at scheduled times. The company is in the process of enhancing the system to assist pharmaceutical companies that need to deliver key communications to select individuals.
"Pharmaceutical companies need help communicating directly with medical professionals in an affordable and secure manner. Face-to-face opportunities such as dinners, office visits or other personal events are too expensive and have fallen out of favor for a variety of reasons," stated Jack Yeager, CEO of Sylogent. "Budgets have been dramatically cut, but it remains critical for medical professionals to receive information from drug and device manufacturers. Our solution utilizes scheduled video broadcasts that play on smartphones, tablets or computers."
"The enhanced solution, to be called MedCast, will also include tools that permit presenter and participant interaction, the ability to complete surveys, and functionality that will permit doctors to order samples or other materials during or after the video," stated Yeager. "Sylogent has extensive experience and technology to offer clinical development teams, and this acquisition expands our solutions into the sales and marketing side of the business."
Sylogent's vision with its cross-device media player MedCast is to provide its clients with an affordable yet effective communication solution. MedCast will provide a 24/7 communication platform that can be viewed on any computer or device (iPhone, Android, iPad) by any professional with cellular or internet access.
MedCast represents Sylogent's first technology solution aimed at the brand, marketing and sales groups. The system is expected to launch in the first quarter of 2012. "Our goal is to drive effective, convenient and secure communications at the lowest price possible," said Yeager.
Sylogent provides software solutions to the pharmaceutical and medical device industries. We create value by automating core processes thereby saving our clients millions of dollars through better compliance, improved efficiencies and lower technology costs.
MarketWire Press Release
SYLOGENT LAUNCHES PHARMA APPROVALS MODULE
NOVEMBER 10, 2011 - MARKETWIRE
NEWTOWN, PA--(Marketwire - Nov 10, 2011) - Sylogent today announced that it completed development on its Approvals Module and the company expects to deploy the system for several clients by year's end.
"Biopharma and device company SOPs typically require an extensive approval process before clinical data, documents or other materials can be disclosed," stated Jack Yeager, CEO of Sylogent. "In talking with our industry contacts, we understand that the approval process typically is managed by using a home-grown system, an offline committee, or requires executive approvers to learn multiple systems to manage a piecemeal approvals process."
"We have identified an increasing demand for a single, simple, disclosure approvals system," stated Yeager. "Sylogent has extensive experience in managing approvals processes that we gained through our PubSTRAT, VCTR, ReCAP, and Publish II solutions currently active in a wide range of customers."
With the Approvals Module Sylogent envisions a configurable solution that will centralize and streamline the enterprise approvals processes in research, clinical development and publication planning. The Approvals Module will offer direct entry for new approval requests, but also can receive requests routed from third-party applications.
The Approvals Module represents the first module in Sylogent's new SylogIQ Platform that aims to organize, standardize and automate the clinical development process for our customers. "Our goal is to drive compliance, maximize efficiencies and dramatically reduce operating costs. We aim to save our customers millions of dollars," said Yeager.
"As we work with our customers' data, we've become aware of a growing need for standardized data and metadata in clinical development systems, to reduce re-keying or data migration workloads as data are moved from protocol to trial registration to results reporting to publications, with all the many steps in between," stated Yeager.
Sylogent provides software solutions to the pharmaceutical and medical device industries. We create value by automating core processes thereby saving our clients millions of dollars through better compliance, improved efficiencies and lower technology costs.
MarketWire Press Release
SYLOGENT EXHIBITS AT DIA ANNUAL MEETING
JUNE 19-22, 2011 - booth 2053
Sylogent will exhibit at the 2011 Drug Information Association Annual Meeting June 19-22 in Chicago, IL. The company will feature demonstrations of its new Clinical Development Management System, SylogIQ.
Sylogent provides software solutions to the pharmaceutical and medical device industries. We create value by automating core processes thereby saving our clients millions of dollars through better compliance, improved efficiencies and lower technology costs.
SYLOGENT SPONSORS ISMPP 7th ANNUAL MEETING
April 4-6, 2011
The International Society for Medical Publication Professionals (ISMPP)
is pleased to announce the opening of registration for its 6th annual
meeting, “Delivering Value and Driving Advocacy in Medical
Publications.” The meeting will run from April 19 to 21, 2010, in
Arlington, VA, at the Crystal Gateway Marriott.
ISMPP has created an exciting program that focuses on two of the most
critical factors that are relevant to all who work in medical
publications — value and advocacy. Both are integral to ensuring that
medical publication professionals can continue to contribute to the
dissemination of the results of clinical trials with accuracy,
transparency, and integrity.
To address these issues, this year’s plenary sessions will explore such
topics as the impact of guidelines and regulations, including GPP-2;
ISMPP’s advocacy activities; and insights of journal editors. Unique
this year to the journal editors’ segment is the rollout of an authors’
tool kit that has been developed by editors of top-tier medical
journals. As in the past, the meeting will also offer half-day pre- and
post-conference workshops and original ISMPP member research
presentations.
SYLOGENT SPONSORS WEBINAR WITH CBI
FEBRUARY 24th 11:00am EST - The Perfect Storm: Conflicts Arising from Clinical Data Disclosure and Publication Planning
Wherever you look there is evidence of a growing storm of activity
around clinical trial registration and results disclosure (CTRR). This
mandatory registration for most protocols and full disclosure of trial
result summaries within a year of primary (outcome) completion date has
significant implications for publication planning professionals.
This webinar will examine current state of CTRR from its epicenter to
its ever-expanding margins. It will then walk delegates through the
implications for publication professionals and suggest practical
strategies to help insure that your primary journal publication is timed
as close as possible to your result disclosure.
Key Learning Points:
- What regulations and guidances are in place today that mandate CTRR?
- What new CTRR regulations and guidances are expected in the short term?
- What are the main implications of CTRR for trial sponsors?
- How does this impact publication planning teams?
- How are successful publication teams evolving their processes to adapt to these important environmental changes?
SYLOGENT SPONSORS DISCLOSURE CONFERENCE
April 27-28, 2011 Philadelphia, PA
CBI’s 6th Forum on Clinical Trial Registries and Results Databases - Over the last several years, the global regulatory framework for
clinical trial transparency has evolved considerably. With rule-making
expected domestically, the highly anticipated release of EudraCT Version
8 and the continued proliferation of national registries around the
globe all planned for 2010, this trend is sure to continue.
In order to remain compliant, those charged with trial registration and
results disclosure must capitalize on valuable opportunities to interact
with likeminded professionals and develop best practices for a global
compliance program.
As one of the industry’s most revered forums since 2006, CBI’s 6th
Clinical Trial Registries and Results Databases Conference boasts the
perfect mix of topics in 2011.
In addition to expert perspectives from U.S. and European based
speakers, the program also features representatives from national
registries such as Chile, India and the Netherlands. Register today and
don’t miss your only opportunity to obtain essential information
directly from the source!
SYLOGENT SPONSORS CLINICAL DATA DISCLOSURE CONFERENCE
January 12-13, Washington, DC - EXL 5TH CLINICAL DATA DISCLOSURE CONFERENCE
Beginning in 2007, the Food and Drug Administration Act (FDAAA) required
drug and device companies to register their investigational studies in
clinical trial databases. FDAAA stated that Clinicaltrials.gov was the
repository that must be used and required the registration of new
clinical studies and the disclosure of results for completed studies.
The principle behind clinical trial reporting is to increase
transparency into the drug and device development process, and by doing
so, alleviate any doubts the public may have about the conduct of
clinical trials, and safety of drug and device companies’ products.
In recent years, the industry has encouraged greater transparency in the
drug and device development process. New laws and guidances from
regulatory agencies and health organizations require that drug and
device companies provide transparency into their clinical studies.
Clinical disclosure is becoming increasingly crucial and is a necessity
for companies to understand and comply.
We hope you can join us for this valuable educational and networking opportunity.
Read More
SYLOGENT RELEASES CLINICAL REGISTRY SOLUTION
NOVEMBER 1, 2010
Sylogent today announced the release of the 2.1 version of its Clinical Trial Registration and Results Disclosure solution, VCTR (Victor).
"Current customers are anticipating significant savings in cost and time, as well as improvements in data accuracy, as a result of this release," stated Jack Yeager, CEO of Sylogent. "Exporting data from SAS and importing it into VCTR will mean that customers will no longer be relying on expensive and frequently overstretched professionals to manually enter this complex dataset."
Industry statistics indicate that manual data entry into the FDAAA format can take between 20 and 40 hours and often requires significant input from highly compensated resources such as biostatisticians.
"Part of the challenge sponsors face is that SAS only offers limited export to XML capabilities, requiring subsequent transformation into FDAAA format," stated Yeager. "We solved this problem by developing a proprietary flat file data format so that customers can get data out of SAS quickly and easily, and then import it into VCTR with just a few clicks. Once in VCTR, data is transformed into FDAAA format, validated, and ultimately routed through configurable review and approval processes prior to posting to the registries."
Sylogent provides customers with the option to import any individual FDAAA result section (such as Adverse Events), or all major data-intensive sections, offering up to 90% of data entry automation.
The company worked closely with SAS programming teams from two leading pharmaceutical customers to perfect the schemas and data import process, which was extensively tested prior to production launch.
"We focus on delivering the best service, solutions and value for our clinical data disclosure customers," stated Yeager.
MarketWire Press Release
SYLOGENT COMPLETES ACQUISITION OF PEERVIEW
July 14, 2009
Sylogent today announced that it has completed its acquisition of PeerView, Inc. This asset acquisition agreement brings to Sylogent the market-leading publication planning solutions PubSTRAT™ and the innovative VCTR™ clinical registry solution.
As a result of the transaction Sylogent has relocated its headquarters to the historic Stocking Works in Newtown, PA, and will maintain its satellite office in Somerville, MA. Most key PeerView staff joined Sylogent, thus ensuring minimal disruption to the broad and long-standing customer relationships.
The PubSTRAT™ Web Suite™, comprising Conference Authority™, Journal Selector™, PubSTRAT™, and PubSTRAT™ CiteCentral™ is a leading publication planning solution that is in regular use by a growing number of customers in the pharmaceutical and biotech industries.
VCTR™ is rapidly emerging as the leading platform to support compliance with the increasingly complex clinical data disclosure process for biotech and pharmaceutical companies. Clinical data disclosure includes the timely registration and updating of clinical trials information as well as the posting of trial results to publicly accessible websites. The VCTR platform enables customers to significantly reduce the burden of maintaining large and complex clinical development programs in full compliance with the ever-changing US and International regulations.
“We are excited to welcome our new colleagues to Sylogent and to bring add the PeerView products and services to our offerings,” stated Jack Yeager, CEO and Founder of Sylogent. He continued, “The addition of PeerView is seen as critical to the planned growth of Sylogent, both organically and through strategic acquisitions.”
Sylogent is focused on providing workflow solutions and services that support the late clinical development and early commercialization business processes of our pharmaceutical and biotech customers.
